A5037145238- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- PI3K/AKT/mTOR signaling in cancer
- Synthesis and biological activity
- BRCA gene mutations in cancer
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related molecular mechanisms research
- Peptidase Inhibition and Analysis
- Medicine and Dermatology Studies History
- Multiple Myeloma Research and Treatments
- Chromatin Remodeling and Cancer
- Fatty Acid Research and Health
- Mechanisms of cancer metastasis
- Infant Nutrition and Health
- Child and Adolescent Psychosocial and Emotional Development
- Growth Hormone and Insulin-like Growth Factors
- Extracellular vesicles in disease
- Estrogen and related hormone effects
The University of Kansas Cancer Center
2017-2024
University of Kansas Medical Center
2016-2023
University of Kansas
2023
Indiana University
2022
Portland State University
1981
University of Pittsburgh
1955
Magee-Womens Hospital
1955
Addition of pembrolizumab to anthracycline-based chemotherapy improves pathologic complete response (pCR) and event-free survival (EFS) in triple-negative breast cancer (TNBC). The efficacy anthracycline-free chemoimmunotherapy TNBC has not been assessed.
Abstract Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim the NeoSTOP multisite randomized phase II trial was assess efficacy anthracycline-free anthracycline-containing neoadjuvant regimens. Patients Methods: aged ≥18 years with stage I–III TNBC were (1:1) receive either paclitaxel (P) weekly × 12 AUC6 every 21 days 4 followed...
Abstract Purpose: PIK3CA mutations are common in breast cancer and promote tumor progression treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel patients with HER2-negative metastatic (MBC). Patients Methods: Eligible had MBC any number prior chemotherapies. Phase I was 3+3 dose-escalation design three dose levels (250, 300, 350 mg) daily 100 mg/m2 administered on days 1, 8, 15 every 28 days. II according to Simon's two-stage...
513 Background: Addition of pembrolizumab to anthracycline-taxane-platinum chemotherapy improves pathologic complete response (pCR) and event free survival (EFS) in TNBC. Aim this study was assess the efficacy anthracycline neoadjuvant regimen plus carboplatin docetaxel (Cb+D) Methods: In multicenter study, eligible patients with stage I-III TNBC received (AUC 6) + (75 mg/m 2 ) (200 mg) every 21 days x 6 cycles. The primary endpoint pCR (no evidence invasive tumor breast axilla). Secondary...
Triple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone (PR) immunohistochemistry expression <1% absence of HER2 amplification/overexpression. HER2-negative with low ER/PR (1-10%) has a gene profile similar to TNBC; however, real-world treatment patterns, chemotherapy response, endocrine therapy benefit, survival outcomes for the Low-ER group are not well known. 516 patients stage I-III ≤10% who were enrolled in multisite prospective registry...
Abstract Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify RD could help individualize adjuvant and inform future trials. We aim investigate the impact of circulating tumor DNA (ctDNA) status burden (RCB) class on outcomes in TNBC RD. analyze end-of-treatment ctDNA 80 who enrolled a prospective multisite registry. Among patients, 33% positive (ctDNA+) RCB distribution...
Abstract Purpose: Stromal tumor-infiltrating lymphocytes (sTIL) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in the setting of anthracycline-based chemotherapy. The impact sTILs on refining beyond prognostic information provided by pCR anthracycline-free neoadjuvant chemotherapy (NAC) is not known. Experimental Design: This a pooled analysis two studies where patients stage I (T&gt;1 cm)–III TNBC received...
TPS629 Background: Neoadjuvant chemoimmunotherapy is recommended for patients with high risk early stage TNBC. The 5 drug KEYNOTE-522 neoadjuvant regimen involves 5-6 months of treatment and associated suboptimal completion due to toxicity. Approaches deescalate without compromising outcomes highly chemosensitive disease are needed. Stromal tumor infiltrating lymphocyte (sTIL) enrichment positively pathologic complete response (pCR) in TNBC may be useful identify whom de-escalation might...
IT IS known that serum protein-bound iodine (PBI) levels may be altered in circumstances other than hyper- or hypothyroidism (1). For example there are the increases associated with pregnancy (2–5) and muscular dystrophy (6, 7) decreases which noted cirrhosis (8) subjects receiving cortisone ACTH (9–14). It has also been reported patients leukemia lymphomata an increase PBI level basal metabolic rate above normal range (15–18). In none of instances listed have mechanisms involved particular...
1076 Background: Histone deacetylase inhibitors (HDACi) upregulate genes involved in antigen presentation machinery and increase expression of natural killer group 2, member D ligands (NKG2DL), thus resulting enhanced tumor cell recognition response to PD-1/CTLA-4 blockade. Cisplatin HDACi combination synergistically induces cytotoxicity, apoptosis, DNA damage. This phase I-II trial investigated romidepsin plus cisplatin nivolumab (PD-1 inhibitor) mTNBC. Patients Methods: Eligible patients...
Abstract Introduction: The TNBC-DX risk score includes the 14-gene immunoglobulin (IGG) immune signature, tumor size, and nodal status has shown prognostic value for survival in early-stage TNBC (B. Conte et al., ESMO Breast 2021). However, currently unknown are of IGG signature 1) predicting pathologic complete response (pCR) following neoadjuvant therapy, 2) outcomes context anti-PD1 treatment. Here, we assessed patients with treated chemoimmunotherapy (NeoPACT; NCT03639948) chemotherapy...
507 Background: TNBCs with enrichment of stromal tumor-infiltrating lymphocytes (sTILs) and/or immune gene expression are more sensitive to neoadjuvant systemic therapy (NAST) and exhibit higher rates pathologic complete response (pCR). Other biomarkers, including proliferation, also prognostic in TNBC patients treated NAST. We aim investigate the impact proliferation on efficacy NAST sTIL-high sTIL-low TNBC. Methods: 110 chemoimmunotherapy (Carboplatin+Docetaxel+Pembrolizumab) phase II...
578 Background: TNBC patients with RD after neoadjuvant systemic therapy (NAST) have high risk of recurrence. Biomarkers to risk-stratify could individualize adjuvant and inform trials. We aim investigate the impact circulating extracellular vesicle (EV)-derived non-coding RNAs (exo-ncRNAs) on outcomes in RD. Methods: The study population included 79 post-NAST available end-of- treatment plasma samples enrolled an IRB-approved multisite prospective registry. EVs their associated exo-ncRNAs...
516 Background: Addition of neoadjuvant carboplatin (Cb) to paclitaxel (T) followed by doxorubicin + cyclophosphamide (AC) improves pathologic complete response (pCR) rate compared T/AC in TNBC. An anthracycline-free regimen Cb plus docetaxel (D) also yields high pCR rates TNBC, and patients achieving with this demonstrate excellent 3-year outcomes without adjuvant anthracycline. This study was designed compare the efficacy regimens CbT→AC CbD Methods: In multicenter study, eligible stage...
Abstract Introduction TNBC is overrepresented in Black women, and patients with have worse clinical outcomes compared to non-Black patients. This disparity likely results from racial differences clinical, biological, demographic features of social determinants health. Neoadjuvant chemoimmunotherapy current standard care for high-risk TNBC. However, been poorly represented immunotherapy trials, making it difficult assess comparative efficacy Methods We utilized two neoadjuvant trials the...
Abstract Background: Stromal tumor-infiltrating lymphocytes (sTILs) quantification is associated with pathological response to neoadjuvant chemotherapy (NAC) and long term outcomes in setting of adjuvant anthracycline based chemotherapy. A previous study TNBC patients treated shows that at a cut point 30%, sTILs can up downstage traditional AJCC stage groups. Additive impact on refining beyond TNM for anthracycline-free not known. This aimed investigate large cohort Docetaxel plus...
Abstract Objectives/Rationale: Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence and death. While multiple prognostic biomarkers associated response to NAST have been identified, adaptive resistance mechanisms remain poorly understood. Identifying characterizing can illuminate novel therapeutic approaches improve outcomes TNBC RD. Methods: Total RNA was isolated from pre-treatment paired surgical...
<div>AbstractPurpose:<p>Stromal tumor-infiltrating lymphocytes (sTIL) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in the setting of anthracycline-based chemotherapy. The impact sTILs on refining beyond prognostic information provided by pCR anthracycline-free neoadjuvant chemotherapy (NAC) is not known.</p>Experimental Design:<p>This a pooled analysis two studies where patients stage I (T>1...
<div>AbstractPurpose:<p>Stromal tumor-infiltrating lymphocytes (sTIL) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in the setting of anthracycline-based chemotherapy. The impact sTILs on refining beyond prognostic information provided by pCR anthracycline-free neoadjuvant chemotherapy (NAC) is not known.</p>Experimental Design:<p>This a pooled analysis two studies where patients stage I (T>1...
<p>Survival by adjuvant chemotherapy use among patients with residual disease</p>
<p>Supplementary Methods</p>